logo

For the Inventor, By the Inventor

Middlesex, United Kingdom

Domantis Limited


USPTO Granted Patents = 38

% Expired Patents = 39.5



Forward Citations = 432

Loading Chart...
Loading Chart...

56 inventors (with patents filed for the assignee):

goldMedal Suzanne J Suchard (15 out of 25 patents)

silverMedal Olga Ignatovich (13 out of 20 patents)

bronzeMedal Steven Grant (13 out of 20 patents)

4.  Ian M Tomlinson (13 out of 20 patents)

5.  Steven G Nadler (12 out of 21 patents)

6.  Steve Holmes (11 out of 28 patents)

7.  James K Tamura (9 out of 11 patents)

8.  James William Bryson (9 out of 19 patents)

9.  Philip Drew (9 out of 9 patents)

10.  Anish Suri (9 out of 9 patents)

11.  Aaron Paul Yamniuk (9 out of 33 patents)

12.  Laura Price (6 out of 9 patents)

13.  Robert P Rehfuss (6 out of 10 patents)

14.  Brendan Classon (6 out of 6 patents)

15.  Christopher Plummer (6 out of 7 patents)


Core Competencies:
Monovalent Antibodies
CD28 Binding
CD40 Antagonists
Pulmonary Diseases
Nucleic Acids
Bispecific Fusion Antibodies
Dendritic Cells
VEGF Binding
EGFR Ligands
Polypeptides
Antibody Variable Domains
Autoimmune Treatment

38 patents:

1. 12012452 - Compositions monovalent for CD28 binding and methods of use (2024-06-18),
2. 11180567 - Antibody polypeptides that antagonize CD40L (2021-11-23),
3. 11136406 - Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40 (2021-10-05),
4. 10919965 - Compositions monovalent for CD28 binding and methods of use (2021-02-16),
5. 10544228 - Nucleic acids encoding antibody polypeptides that antagonize CD40 (2020-01-28),
6. 10196451 - Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L (2019-02-05),
7. 10072089 - Polypeptides, antibody variable domains and antagonists (2018-09-11),
8. 9908937 - Compositions monovalent for CD28 binding and methods of use (2018-03-06),
9. 9765150 - Antibody polypeptides that antagonize CD40L (2017-09-19),
10. 9629909 - Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue (2017-04-25),
11. 9562090 - Polypeptides, antibody variable domains and antagonists (2017-02-07),
12. 9475879 - Antibody polypeptides that antagonize CD40 (2016-10-25),
13. 9321832 - Ligand (2016-04-26),
14. 9228018 - Antibody polypeptides that antagonize CD40L (2016-01-05),
15. 9085629 - Compositions monovalent for CD28 binding and methods of use (2015-07-21),
Company Overview
Domantis Limited is a biotechnology company based in Middlesex, UK, specializing in the development of innovative therapeutic solutions. The organization focuses on harnessing the potential of domain antibodies, which are engineered to target specific proteins involved in various diseases. Domantis is dedicated to advancing research in the fields of immunology and oncology, aiming to create effective treatments that address unmet medical needs. Their work emphasizes precision medicine and the application of cutting-edge biotechnological advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

38 Patents

#11 in Middlesex

#471 in United Kingdom

#17,831 in the World

Middlesex, GB
Middlesex, United Kingdom

Domantis Limited

Forward Citations = 432

56 inventors:

goldMedal Suzanne J Suchard (15 out of 25 patents)

silverMedal Olga Ignatovich (13 out of 20 patents)

bronzeMedal Steven Grant (13 out of 20 patents)

4.  Ian M Tomlinson (13 out of 20 patents)

5.  Steven G Nadler (12 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Domantis Limited. Retrieved from https://idiyas.com/company/domantis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…